Case

Device lead-associated TR: Is the lead really the cause?

A pacing lead crossing the tricuspid valve does not necessarily cause TR. This case explores how leaflet motion, lead position, jet origin, and right-heart remodeling help distinguish mechanical lead interference from functional TR — and why both mechanisms may coexist.

Clinical scenario

82-year-old pacing-dependent man with progressive edema. TTE: moderate-to-severe TR, marked RA/RV enlargement, and an RV pacing lead running close to the posterior tricuspid leaflet.

The question this case asks: is the lead causing the TR, is this functional TR from right-heart remodeling, or is it both — and which echo findings tell them apart?

Case presentation

An 82-year-old man had a dual-chamber pacemaker implanted 9 years ago for sick sinus syndrome and has been pacing-dependent for the past 3 years. Over the last 6 months he has developed progressive leg edema and a clear decline in exercise tolerance. He has had no syncope. He takes furosemide and has been increasing the dose on his own.

TTE shows moderate-to-severe TR by qualitative assessment and marked RA/RV enlargement. The RV pacing lead runs close to the posterior tricuspid leaflet. Posterior leaflet motion appears restricted, and malcoaptation is suspected next to the lead.

Echo findings

FindingValueHow to read it
TR grade (qualitative)Moderate-to-severeSignificant TR; integrated severity not yet settled
Vena contracta0.70 cmAt the severe threshold (≥0.70 cm) — one severe-range parameter, not a final grade on its own
Lead positionRV lead near the posterior leafletPossible mechanical contributor — position alone does not prove causation
Posterior leafletRestricted motion, malcoaptation suspected near the leadThe key mechanism clue — needs dynamic confirmation
RA / RVMarkedly enlargedChronic right-heart volume overload; also a driver of functional TR
TAPSE13 mmBelow 17 mm — suggests reduced RV longitudinal function
IVC26 mm, no respiratory variationElevated RA pressure and venous congestion
Estimated PASP45 mmHgEstimate only — may be unreliable in significant TR
Hepatic vein flowSystolic blunting; no systolic flow reversalSupports elevated RA pressure. Not the severe-TR sign of systolic reversal — but not evidence against severe TR either

The severity picture is not fully consistent. The vena contracta sits exactly at the severe threshold, but the qualitative grade is moderate-to-severe and the hepatic veins show blunting rather than systolic reversal. Blunting is an intermediate, nonspecific finding: it fits moderate TR, but it also reflects high RA pressure and is affected by heart rhythm, so it neither confirms nor excludes severe TR. VC is a single linear measurement and can over- or underestimate a noncircular or eccentric orifice — which is common when a lead distorts coaptation. Before calling this severe TR, add EROA and regurgitant volume by PISA, the CW Doppler contour, and, if available, 3D vena contracta area.

The right-heart findings also need careful reading. TAPSE 13 mm suggests reduced RV function, but TAPSE measures only longitudinal motion at one point. Confirm with RV fractional area change, RV free-wall strain, or 3D RV ejection fraction. IVC plethora and hepatic vein blunting reflect high RA pressure and congestion — they do not grade TR severity. The estimated PASP of 45 mmHg comes from the TR jet; in significant TR, early RA-RV pressure equalization can make that estimate unreliable, so treat it as approximate. TR Vmax is a pressure gradient, not a measure of TR severity.

Question 1 — Echo mechanism

Which finding most strongly supports the lead directly contributing to the TR?

  1. A.The pacemaker lead crosses the tricuspid valve
  2. B.Systolic motion of the leaflet is restricted where it contacts the lead, and malcoaptation occurs at that same site
  3. C.The RA and RV are markedly enlarged
Explanation
  • A. Almost every transvenous RV lead crosses the valve. Seeing a lead is not the same as proving it causes TR.
  • B. ✓ Best answer — The key is whether leaflet restriction and lead contact occur at the same location — and whether the regurgitant orifice sits there too. That match is what supports mechanical interference.
  • C. Right-heart enlargement is a cause and a consequence of TR. It points at least as much toward functional TR as toward the lead.

Lead presence alone cannot establish causation. Localized restriction of leaflet motion at the point of lead contact, with malcoaptation at that same location, is the strongest evidence for mechanical interference. It does not exclude coexisting functional TR — in this patient, the marked RV and RA enlargement makes some functional component likely.

Four ways a lead can interfere with the valve

The 2024 European Heart Journal review on CIED-related TR describes four lead-valve interactions, each with a recognizable 3D echo pattern. The question to ask for each one is: what does the leaflet do in diastole, and what does it do in systole?

A. Impingement — the lead gets in the way of closure

  • Diastole: the leaflet and lead are separate, and the leaflet opens relatively normally.
  • Systole: the closing leaflet meets the lead and its excursion is reduced at the contact point.
  • A coaptation defect forms at that site, and the jet originates there.

B. Adhesion — the lead and leaflet are stuck together

  • The leaflet and lead move together throughout the cardiac cycle — they never separate, even in diastole.
  • Systolic leaflet excursion is restricted because the leaflet is tethered to the lead.
  • Typically a problem of chronic leads, as fibrous tissue builds up over years of dwell time.

C. Perforation — the lead passes through a leaflet

  • The lead traverses the leaflet body rather than passing through the orifice.
  • A focal defect is seen in the leaflet, with color Doppler suggesting regurgitation through it.
  • 3D en face views of the leaflet surface can reveal a perforation that 2D views miss.

D. Subvalvular interference — the lead tangles with the chordae

  • The lead is caught in, or presses on, the chordae or subvalvular apparatus.
  • Chordal motion is limited, so the leaflet cannot close properly even though the lead may not touch the leaflet itself.
Impingement vs adhesion — the distinction that matters most
ImpingementAdhesion
DiastoleLeaflet separates from the lead and moves relatively normallyLeaflet stays with the lead
SystoleLeaflet contacts the lead; excursion reducedLeaflet moves with the lead; excursion reduced
What to look forContact that appears only in systoleLead and leaflet moving as one through the whole cycle
Why it mattersThe leaflet itself is free; restriction depends on lead positionThe leaflet is attached to the lead — important when extraction risk is assessed

Mechanical lead interference or functional TR?

Functional TR is common in patients with transvalvular leads, and it can look similar on 2D imaging. Compare the findings below and ask which pattern explains the regurgitant orifice.

FindingLead-related mechanical TRFunctional TR
Leaflet motionLocalized restriction at lead contactTethering or malcoaptation from chamber remodeling
Lead relationshipDirect interaction with the affected leafletLead may be present without direct interference
Regurgitant jetMay originate near the lead-contact siteOften related to a broader coaptation defect
Annular dilationMay or may not be presentOften an important driver
RV enlargementMay coexistProminent in ventricular functional TR
3D echoDemonstrates lead-leaflet interactionDemonstrates annular dilation, tethering, and coaptation gap
Functional TR comes in two forms
Ventricular functional TRAtrial functional TR
Main driverRV dilation and shape changeRA enlargement and tricuspid annular dilation
LeafletsTethered by displaced papillary musclesNot tethered; malcoaptation mainly from annular dilation
RV functionOften reducedOften relatively preserved
Typical backgroundPulmonary hypertension, left-sided heart disease, RV myocardial diseaseAtrial fibrillation, RA enlargement

The mechanisms are not mutually exclusive

Mechanical lead interference and functional TR can coexist. A lead can restrict one leaflet while RV dilation tethers the others and the annulus enlarges. An eccentric jet, or a jet that happens to lie near the lead, does not on its own prove that the lead is responsible.

In this patient, both are plausible. Posterior leaflet restriction near the lead points to mechanical interference, while marked RA/RV enlargement and reduced TAPSE suggest a ventricular functional component. Pacing-induced cardiomyopathy is worth considering after 3 years of pacing dependence, but RV enlargement and TR are not enough to diagnose it. That requires the RV pacing burden, LV ejection fraction and any decline from prior studies, the paced QRS duration, and comparison with earlier echocardiograms.

What 3D echocardiography adds

  • On 2D imaging, the lead and the leaflets are often not seen in the same plane, so their relationship can be misjudged.
  • 3D TTE lets you view the tricuspid valve en face, from the atrial or ventricular side.
  • Identify the anterior, posterior, and septal leaflets, and determine which leaflet the lead touches.
  • Follow the lead and the leaflet through the whole cardiac cycle — separation in diastole with contact in systole (impingement) versus constant co-movement (adhesion).
  • Locate the coaptation defect and the jet origin with 3D color, and check whether they match the contact site.
  • When TTE windows are inadequate, consider TEE and 3D multiplanar reconstruction.
  • TEE is not automatically superior: the tricuspid valve lies far from the esophageal probe, and lead shadowing and reverberation can obscure the leaflets. Choose the modality that gives the best images in that patient.
Views to use — what each can show depends on image quality
ViewWhat to look forLimitation
Apical 4-chamber / RV-focusedLead course, septal and anterior or posterior leaflet motion, jet directionLeaflet identity varies with probe angulation
Parasternal RV inflowLead crossing, anterior and posterior leaflet motionMay not show the full coaptation line
SubcostalLead path, IVC and hepatic veins; an alternative windowLower resolution for leaflet detail
3D TTE en faceWhich leaflet the lead touches; coaptation gap; perforationDepends on the acoustic window; lead artifact
TEE midesophageal viewsLead-leaflet relationship and jet origin, especially with poor TTE windowsValve is in the far field; shadowing
TEE transgastric short-axisShort-axis view of all three leaflets and lead positionNot obtainable in every patient
3D multiplanar reconstructionLead position at the coaptation level; precise leaflet identificationRequires good-quality 3D data sets

Teaching extension: a hypothetical 3D study

This finding is added for teaching and was not part of the original study. Suppose 3D TTE shows the lead lying against the posterior leaflet: separated in diastole, in contact during systole, with reduced posterior leaflet excursion. 3D color places the main jet origin at that contact site. The same view also shows annular dilation and a coaptation gap extending away from the lead. Together, this would point to impingement plus a functional component.

Question 2 — Next step

Echo supports mechanical lead interference, but there is also RV enlargement and reduced RV function. What is the appropriate next step?

  1. A.Joint evaluation by the electrophysiology (device) team and the valve team
  2. B.Decide on lead extraction now because the TR is severe
  3. C.Attribute the TR to functional TR because the RV is enlarged, and stop evaluating the lead
Explanation
  • A. ✓ Best answer — Both the lead and the remodeled right heart are contributing. Decisions about each depend on the other.
  • B. Extraction does not address the functional component, carries its own risk in a pacing-dependent patient with a 9-year-old lead, and severity is not yet fully confirmed.
  • C. This ignores direct evidence of lead-leaflet interaction that could change the treatment plan.

Lead-related mechanical injury and functional TR may both be contributing. Whether to extract, revise, or reposition the lead, use an alternative pacing strategy, or intervene on the valve depends on pacing dependence, lead dwell time, the likelihood of adhesion, RV function, valve anatomy, and procedural risk. Those factors have to be weighed together by a specialist team.

Why the device and valve teams need to decide together

The device team assesses lead type and dwell time, lead integrity, pacing dependence, extraction risk, and alternative pacing options such as leadless or conduction-system pacing. The valve team assesses integrated TR severity, leaflet and annular anatomy, RV function, and surgical or transcatheter options. In this patient the questions interlock: removing a lead may not fix TR driven by RV remodeling, and a transcatheter tricuspid device could trap a lead that may later need to come out.

What this case — and the tool — do not decide

Neither this case nor the TR Intervention Navigator recommends lead extraction, revision, repositioning, or a specific valve procedure. Those choices are individualized by the device-valve team.

Tool interpretation

  • TR Severity Tool: VC 0.70 cm counts as a severe-range signal. Hepatic vein blunting is treated as a moderate-range finding that conflicts with it. With the qualitative grade left blank or entered as moderate, the tool returns 'discordant / indeterminate TR' and asks for an integrated severity assessment; entered as severe, it returns 'severe TR pattern.' Treating blunting as conflicting evidence is a simplification — clinically it is nonspecific rather than proof that TR is not severe. With device lead entered as the mechanism, the Severity Tool already lists device-valve team evaluation as a next step, even at a discordant grade.
  • TR Intervention Navigator, before severity is settled: entering severity as uncertain or discordant routes to 'confirm severity and mechanism first.'
  • TR Intervention Navigator, once severe TR is confirmed: entering mechanism as device lead associated — or lead present with lead interference suspected — routes to 'device-valve team evaluation.' A moderately or severely reduced RV, or end-organ congestion, adds a flag for higher procedural risk without changing that pathway.

The tool's branch point is not the referral threshold

The Navigator moves to device-valve team evaluation only after severe TR is confirmed. That condition decides which pathway the tool displays; it is not a rule for when to ask the specialists. This patient has progressive symptoms, TAPSE 13 mm, VC at the severe threshold, and venous congestion. Talking to the device and valve teams early — while severity is still being confirmed — is reasonable, and the extra measurements can be planned with them. The 2024 European Heart Journal review on CIED-related TR makes the same point: once significant tricuspid disease develops in a patient with a lead, early referral to an expert center and an interdisciplinary approach are needed so that treatment is not delayed, particularly because the chance of TR improving after lead extraction falls with time.

Perioperative considerations

If this patient needs noncardiac surgery before the TR is addressed, two issues need planning: the device and the right heart.

  • Device: confirm pacing dependence, the device type (pacemaker vs ICD), and the date and findings of the most recent interrogation, and contact the device team for a perioperative plan.
  • Magnet response: confirm the device's magnet response in advance. It differs between pacemakers and ICDs and between manufacturers.
  • Electromagnetic interference: with monopolar electrosurgery, especially above the umbilicus, oversensing can inhibit pacing in a pacing-dependent patient.
  • Programming: whether to use asynchronous pacing — by magnet or by reprogramming — depends on the device type, surgical site, expected EMI, pacing dependence, and whether a magnet can be kept in place outside the sterile field. Restore the original settings and have the device checked after surgery as planned.
  • Right heart: with reduced RV function and venous congestion, aim for an appropriate preload and avoid fluid overload.
  • Pulmonary vascular resistance: avoid sudden rises from hypoxemia, hypercapnia, acidosis, and high airway pressures.
  • TEE: consider intraoperative TEE for major or high-risk surgery to follow RV function and TR under changing loading conditions. It is not required in every case.

Teaching points

  • Seeing a lead is not the same as proving it causes TR. Look for leaflet restriction and malcoaptation at the exact site of lead contact.
  • Impingement and adhesion differ in diastole: with impingement, the leaflet separates from the lead and contacts it only in systole; with adhesion, the leaflet and lead move together through the whole cycle.
  • Mechanical lead interference and functional TR can coexist. Distinguish ventricular functional TR (RV remodeling, tethering) from atrial functional TR (annular dilation, often with preserved RV function).
  • 3D echo is the key tool for identifying the leaflet, the contact point, and the jet origin. Use TEE when TTE windows are inadequate, not as an automatic upgrade.
  • Integrate severity: VC 0.70 cm is one severe-range parameter. Hepatic vein blunting is not systolic reversal. IVC findings and estimated PASP describe pressure and congestion, not TR severity.
  • When the lead is part of the mechanism, management is decided jointly by the device and valve teams. The TR Intervention Navigator routes to that evaluation once severe TR is confirmed, but with progressive symptoms, RV dysfunction, and congestion, involve the teams early rather than waiting for that branch point. The tool does not choose a treatment.

References

  1. Andreas M, Burri H, Prendergast B, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2024;45(5):346–365. doi:10.1093/eurheartj/ehad783
  2. Hahn RT, Wilkoff BL, Kodali S, et al. Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(20):2002–2014. doi:10.1016/j.jacc.2024.02.045
  3. Deharo JC, Dreyfus J, Bongiorni MG, et al. Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the EHRA and EAPCI of the ESC. Europace. 2025;euaf061. doi:10.1093/europace/euaf061
  4. Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. Circulation. 2024;150(19):e351–e442. doi:10.1161/CIR.0000000000001285
  5. Wan EY, Rogers AJ, Lavelle M, et al. Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association. Circulation. 2024;150(8):e183–e196. doi:10.1161/CIR.0000000000001264
  6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197.

Related valve learning

Apply this in practice

Once severe TR is confirmed, enter mechanism as device lead associated in the TR Intervention Navigator to see the pathway.

Open TR Intervention Navigator